Sanofi has discontinued development of its next-generation mRNA-based seasonal flu vaccine.
According to its 2025 earnings documents, the drugmaker said it halted its phase 1 trial for an mRNA seasonal influenza vaccine and does not anticipate launching an mRNA-based seasonal flu product in the near term.
Sanofi said it will continue developing an mRNA-based pandemic flu vaccine. The company is conducting a phase 1/2 study of an mRNA vaccine using an H5 avian flu platform, which it said has shown encouraging preliminary data.
The company previously said it was working on next-generation mRNA seasonal flu vaccines in June 2023, bringing five different lipids into clinical trials, according to a Jan. 30 news release from the Center for Infectious Disease Research and Policy at the University of Minnesota, which is based in Minneapolis. Sanofi acquired mRNA-focused Translate Bio in 2021 for $3.2 billion as part of its broader investment in mRNA technology.
Sanofi said it remains focused on its existing influenza portfolio, including Fluzone High-Dose and Flublok, both of which are approved by the FDA and target protection against severe flu outcomes.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.